HemaSphere (Jun 2022)
P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
- M. J. van Dijk,
- M. A. Rab,
- B. A. van Oirschot,
- J. Bos,
- C. Derichs,
- A. W. Rijneveld,
- M. H. Cnossen,
- E. Nur,
- B. J. Biemond,
- M. Bartels,
- J. J. Jans,
- W. W. van Solinge,
- R. E. Schutgens,
- R. van Wijk,
- E. J. van Beers
Affiliations
- M. J. van Dijk
- 1 University Medical Center Utrecht, Utrecht
- M. A. Rab
- 1 University Medical Center Utrecht, Utrecht
- B. A. van Oirschot
- 1 University Medical Center Utrecht, Utrecht
- J. Bos
- 1 University Medical Center Utrecht, Utrecht
- C. Derichs
- 1 University Medical Center Utrecht, Utrecht
- A. W. Rijneveld
- 2 Erasmus University Medical Center, Rotterdam
- M. H. Cnossen
- 2 Erasmus University Medical Center, Rotterdam
- E. Nur
- 3 Amsterdam University Medical Center
- B. J. Biemond
- 3 Amsterdam University Medical Center
- M. Bartels
- 1 University Medical Center Utrecht, Utrecht
- J. J. Jans
- 1 University Medical Center Utrecht, Utrecht
- W. W. van Solinge
- 1 University Medical Center Utrecht, Utrecht
- R. E. Schutgens
- 1 University Medical Center Utrecht, Utrecht
- R. van Wijk
- 1 University Medical Center Utrecht, Utrecht
- E. J. van Beers
- 1 University Medical Center Utrecht, Utrecht
- DOI
- https://doi.org/10.1097/01.HS9.0000848860.58516.71
- Journal volume & issue
-
Vol. 6
pp. 1382 – 1383
Abstract
No abstracts available.